FSD Pharma

FSD Pharma is a biopharmaceutical company established by Thomas Fairfull, Zeeshan Saeed, and Anthony Durkacz, with the company’s name representing the first initial of each founder’s last name.

FSD Pharma’s mission is to develop innovative solutions for brain and inflammatory disorders, with a vision of becoming a world-class, innovation-driven biopharmaceutical company that improves the quality of life for patients. The company is dedicated to providing innovative neuro and inflammatory disorders therapies to millions of patients worldwide.

FSD Pharma has three drug candidates in its pipeline: LUCID-MS, LUCID-PSYCH, and FSD-201. LUCID-PSYCH is a psychoactive molecule that has demonstrated excellent results for depression in preclinical models. Manufacturing for this drug candidate has been secured with Covar, and it is currently undergoing IND-enabling studies.